|
Post by slugworth008 on Aug 9, 2016 6:56:59 GMT -5
It doesn't take much to figure out how the OUTsulin character will be used in marketing.
Mike was pretty clear that they would be pushing how fast Afrezza is OUT of a patient much more than how fast it works at the beginning. Whether the post-marketing trial data supports a claim of reduced hypoglycemic blood glucose levels or not remains to be seen. MannKind may not be able to state less hypos, but they have empirical evidence that Afrezza inhaled insulin powder exits the blood much faster than subcutaneous injections of RAA or human insulin.
Did you notice the purple guy's friend, Insulin, on the slide? He looks like a happy, one-eyed robot version of Outsulin. This looks like something that "kids" would identify with...hmmmmm
|
|
|
Post by peppy on Aug 9, 2016 7:07:10 GMT -5
Did you notice the purple guy's friend, Insulin, on the slide? He looks like a happy, one-eyed robot version of Outsulin. This looks like something that "kids" would identify with...hmmmmm for the pediatric development program? screencast.com/t/NOATqZDL label changes
screencast.com/t/CD7QWAbmHrOB
|
|
|
Post by LosingMyBullishness on Aug 9, 2016 7:25:30 GMT -5
I liked that CC. It was second best to the one in January this year (athough I hated Rose' super plain sheet with bad formating).
First time Matt shared what MNKD needed to do to modify the organisation. Pretty impressive. And the in- and outsulin part: Looks very retro and therefore it is pretty modern compared to the cycling grandpa and the shiny people being surprised.
Seriously: The plan sounds decent, the company is mostly organised and does work properly as they get things done. The early indicators look good. A turnaround always starts slow and that is when you should invest (money you have).
|
|
|
Post by agedhippie on Aug 9, 2016 7:36:33 GMT -5
Listening to the conference call again, Mike seems to know what he is doing. sooooooooooo different than the sanofi experience. This time share holders are getting good information. Numbers, reasoning, expectations. I have a difficult time believing insurers are paying 19 dollars a day for insulin, but, I will fall in line, and salute while saying yippee. Your disbelief is justified We know that Medicaid pays just under $33 per pen so $19 equates to 175u of insulin which is a huge amount (I use 25u per day which is fairly typical). To put this into context, assuming 12u cartridges which is the cheapest way to do it, the Afrezza cost for 175u would be $40 again based on Medicaid pricing. I think the insurer pays less less than $3 per day for my insulin.
|
|
|
Post by slugworth008 on Aug 9, 2016 7:39:45 GMT -5
Exactly what I was thinking Peppy.
|
|
|
Post by liane on Aug 9, 2016 7:40:27 GMT -5
|
|
|
Post by slugworth008 on Aug 9, 2016 7:51:31 GMT -5
I just finished reading it...when shazam it disappeared. LOL and thanks Liane
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Aug 9, 2016 8:17:18 GMT -5
I am a terrible actor and way to blunt for most people to handle. heh, hopping in and out of MNKD like a bunny, you get to decide. I know you will hop on again when price starts moving. You see a move coming?
I remember you saying it was hard to get out when volume was 3 million a day, down to 1 million shares moving a day. hard to take. this drug is so good, the clamp study help the heckolee out of this. Now we need the physicians. Pep
Good Morning Pep- Jumping in and out took my losses from 80% down to about 15-20%. I can live with those losses, and an avalanche of mistakes that I learned from. I know how good the drug is as my best friend and old roommate is on Afrezza. I have finger pricked myself for 7 days three times a day to see what a diabetic goes through in that aspect. I completely understand how Afrezza makes the management of the disease so much easier. The unfortunate truth is the drug is that freaking good but that unfortunately does not guarantee its success and that was the toughest pill for me to swallow. Where I re enter all depends on scripts. I am hoping for some FUD to scare a big portion of investors out of their position one of these Fridays and I can get in on a bargain. Or all of these shorts may just wait for the second offering that would dilute my position. So I am just waiting and seeing. IMO theres no reason to add here outside of a trade or some freakish short squeeze, which would suck to miss but not a sound investing strategy. User Reviews are still the same people and how many of them are just self absorbed people that like attention and MNKD share holders certainly give them a ton. I dont want people to lose money but its not my job to care about them. I care about my money, and like you said I am the one that gets to decide!
|
|
|
Post by LosingMyBullishness on Aug 9, 2016 8:21:20 GMT -5
Listening to the conference call again, Mike seems to know what he is doing. sooooooooooo different than the sanofi experience. This time share holders are getting good information. Numbers, reasoning, expectations. I have a difficult time believing insurers are paying 19 dollars a day for insulin, but, I will fall in line, and salute while saying yippee. Your disbelief is justified We know that Medicaid pays just under $33 per pen so $19 equates to 175u of insulin which is a huge amount (I use 25u per day which is fairly typical). To put this into context, assuming 12u cartridges which is the cheapest way to do it, the Afrezza cost for 175u would be $40 again based on Medicaid pricing. I think the insurer pays less less than $3 per day for my insulin. Lets have a look at your argument: A) We know.. : How do you know? B) Medicaid: According to Mikes Pie-Chart Medicaid is 2% of the whole pie. Why do you take Medicaid? C) Mike is refering to WAC, which is the list price, so no discounts etc. If your statement $33 per pen is correct you compare wrong numbers if Medicaid gets discounts. D) Mike stated that the WAC (not including discounts) is $3 per cartridge. I do not know the multiplier for Afrezza compared to what you take but lets take 1.3. So you need 25 u per day and you want to use 12u cartridges -> 25 * 1.3 /12 *$3 = $8.13 per day based on WAC. E) In your last sentence you again compared WAC to your claim about real costs for Medicaid. Does Medicaid gets no discount? E) Finally you stated "I think.. the insurer pays less. " You started with "We know". What changed in between? Do you know or do you think you know the real costs. WAC according to www.fdbhealth.com/policies/drug-pricing-policy/Wholesale Acquisition Cost (WAC) as published by FDB represents the manufacturer's (for purposes of this Drug Price Policy, the term "manufacturer" includes manufacturers, repackagers, private labelers and other suppliers) published catalog or list price for a drug product to wholesalers as reported to First Databank by the manufacturer. WAC does not represent actual transaction prices and does not include prompt pay or other discounts, rebates or reductions in price. First Databank does not perform any independent investigation or analysis of actual transaction prices for purposes of reporting WAC. First Databank relies on manufacturers to report or otherwise make available the values for the WAC data field.
|
|
|
Post by babaoriley on Aug 9, 2016 8:51:42 GMT -5
heh, hopping in and out of MNKD like a bunny, you get to decide. I know you will hop on again when price starts moving. You see a move coming?
I remember you saying it was hard to get out when volume was 3 million a day, down to 1 million shares moving a day. hard to take. this drug is so good, the clamp study help the heckolee out of this. Now we need the physicians. Pep
Good Morning Pep- Jumping in and out took my losses from 80% down to about 15-20%. I can live with those losses, and an avalanche of mistakes that I learned from. I know how good the drug is as my best friend and old roommate is on Afrezza. I have finger pricked myself for 7 days three times a day to see what a diabetic goes through in that aspect. I completely understand how Afrezza makes the management of the disease so much easier. The unfortunate truth is the drug is that freaking good but that unfortunately does not guarantee its success and that was the toughest pill for me to swallow. Where I re enter all depends on scripts. I am hoping for some FUD to scare a big portion of investors out of their position one of these Fridays and I can get in on a bargain. Or all of these shorts may just wait for the second offering that would dilute my position. So I am just waiting and seeing. IMO theres no reason to add here outside of a trade or some freakish short squeeze, which would suck to miss but not a sound investing strategy. User Reviews are still the same people and how many of them are just self absorbed people that like attention and MNKD share holders certainly give them a ton. I dont want people to lose money but its not my job to care about them. I care about my money, and like you said I am the one that gets to decide! There's no place on this board for disciplined traders.
|
|
|
Post by nuklerfizzacist on Aug 9, 2016 9:07:51 GMT -5
wow he sounds nervous is something coming? Well Mr. GS Plant 😄, I've been around this equity, and this board, long enough to say that you will not be successful at your attempt to loosen my grip on my shares. Best of luck to you on your goal of a lower sp. At least all here now understand your motivation for comments like the one you posted here. Yeah, that's the ticket..😉 Cool longs....lol. .jealous?!? 😁😉
|
|
|
Post by silentknight on Aug 9, 2016 9:47:09 GMT -5
I missed the call yesterday but I read the transcript. It sounded like they have their plan in place and are now awaiting on their efforts to begin paying off with increases in sales. I am also waiting (and hoping) for this.
I was also encouraged to learn that their timeline and plans for epi were still intact with plans for 2017 and their IND, presumably for trials. As others have stated, I'm pleased that the company can now communicate on a call in a coherent and confident basis, even though they missed by .01. I think that's why the sell off is happening today.
That being said, I bought more today on the discount. I'm now holding 30K shares and am severely underwater but I'm optimistic that brighter days are ahead.
GLTA longs.
|
|
|
Post by mnholdem on Aug 9, 2016 10:00:23 GMT -5
FWIW, my first thought while listening was that Matt was reading from the script as if trying to reign in his emotions. I still believe that we are only a few days/weeks away from the announcement of a new CEO and I happen to think it will be DeSisto, whose non-compete clause expires September 17, 2016.
As I have previously posted, it's my opinion that when the BoD had to withdraw its offer to employ Duane M. DeSisto as its President and Chief Executive Officer as a consequence of objections raised by Insulet Corporation, the former employer of Mr. DeSisto, that the employment of Mr. DeSisto by MannKind would violate Insulet’s non-competition agreement with Mr. DeSisto (in effect until September 17, 2016) that Matt may have been asked by the BoD to become the interim CEO until DeSisto could be hired.
If DeSisto is hired, then Pfeffer would remain the Chief Financial Officer for MannKind Corporation, as well as his position with Second Sight, another Mann-originated company.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Aug 9, 2016 10:14:46 GMT -5
FWIW, my first thought while listening was that Matt was reading from the script as if trying to reign in his emotions. I still believe that we are only a few days/weeks away from the announcement of a new CEO and I happen to think it will be DeSisto, whose non-compete clause expires September 1, 2016.As I have previously posted, it's my opinion that when the BoD had to withdraw its offer to employ Duane M. DeSisto as its President and Chief Executive Officer as a consequence of objections raised by Insulet Corporation, the former employer of Mr. DeSisto, that the employment of Mr. DeSisto by MannKind would violate Insulet’s non-competition agreement with Mr. DeSisto (in effect until September 17, 2016) that Matt may have been asked by the BoD to become the interim CEO until DeSisto could be hired. If DeSisto is hired, then Pfeffer would remain the Chief Financial Officer for MannKind Corporation, as well as his position with Second Sight, another Mann-originated company. make that September 17, 2016
|
|
|
Post by ilovekauai on Aug 9, 2016 10:17:56 GMT -5
IMO, you're correct in this analysis mnholdem. I've been thinking about this too, for about the past month or so. It would not surprise me at all to see this switch at the top, and would be a coup for MNKD to land DeSisto, who we all know comes very highly regarded. I would welcome the move and see Pfeffer switching over to his more comfortable position as CFO. I also think Matt has done an outstanding job considering where MNKD was in January, compared to today. So much has been accomplished under his leadership. He literally pulled MNKD back from the precipice IMO.
|
|